Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 preladenant dose-ranging study in early Parkinson's disease
2009-013552-72Phase 3Terminated
- Sponsor
- Merck & Co.
- Start
- Jul 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of preladenant in Parkinson's disease (PD) (3 arms), sponsored by Merck & Co. Primary endpoints: Primary efficacy endpoint and Primary safety endpoint. Started Jul 2010; status: terminated.
02
Drugs
preladenant
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on 2009-013552-72.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-013552-72.